antibody-drug conjugates
antibody-drug conjugates
Revolutionary Cancer Treatment: Lonza and Qurient Unite!
🌟 Lonza's Synaffix and Qurient Therapeutics unite for dual-payload ADCs, enhancing cancer treatment with innovative cytotoxic agents! 💊🔬🚀
Lilly’s $5B Virginia Facility: 650 Jobs Coming!
**Excerpt:** 🌟 Eli Lilly is investing $5B in a VA facility, creating 650 jobs and focusing on innovative antibody-drug conjugates! 💼🏗️
Revolutionizing ADC Manufacturing: Boost Efficiency and Safety!
Unlock the future of ADC manufacturing! 🚀 Discover innovations that boost efficiency, ensure safety, and reduce risks. 🔬💡📈 Join the discussion! 💬
Ofichem Boosts Drug Development with New Acquisition!
Ofichem 📈 has acquired Meribel Pharma’s Uppsala site 💊, enhancing drug development and expanding its Nordic client base! 🌍🔗
Samsung Boosts ADC Development with LigaChem Partnership!
Samsung Biologics 🤝 LigaChem join forces for advanced ADC development, boosting manufacturing capabilities and enhancing patient therapies! 💡🏭📈 Biopharma
Lonza Doubles Capacity Adds 200 Jobs in Switzerland!
Lonza expands its Visp facility with two new bioconjugation suites, creating 200 jobs and doubling capacity for antibody-drug conjugates! 🌍🏗️💼📈🌱
Revolutionizing Drug Development: Synaffix and BigHat Team Up!
🌟 Synaffix and BigHat Biosciences join forces! 🤝 Together, they're revolutionizing antibody-drug conjugates with machine learning for safer, more effective treatments. 🚀
Genmab’s $18bn Acquisition Boosts Cancer Pipeline
💥 Genmab is acquiring ProfoundBio for $1.8bn to expand its pipeline of antibody-drug conjugate therapies. 💊🏭🚀
Pfizer’s Bold Investment in Cancer Therapies
📢 Pfizer applauds its big bet in ADCs, a promising cancer treatment area, expecting long-term payoffs and therapeutic advancements. 💪🏥🩺
Massive Growth in UK ADC Facility Boosts Biopharmaceutical Industry
📰 CDMO Piramal bulks out UK ADC facility! 💊🧪 Enhanced capabilities to meet growing demand in biopharmaceutical industry. 🌍👥
